title: PIK3C2G copy number is associated with clinical outcomes of colorectal cancer patients treated with oxaliplatin.
abstract: OBJECTIVE
  To investigate whether the copy number of PIK3C2G is associated with clinical outcomes for stage III colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.
  
  
  METHODS
  A total of 142 CRC patients who received first-line oxaliplatin-based chemotherapy after curative surgery in Ruijin Hospital and The Tenth People's Hospital were recruited in this study. Patients were enrolled between June 2006 and December 2011, with follow-up to January 2014. Quantitative real-time PCR method was used to detect the copy number of PIK3C2G. Cox proportional hazards model and Kaplan-Meier curves were used to analyze the association between PIK3C2G copy number and clinical outcome.
  
  
  RESULTS
  In patients with stage III disease, low copy number of PIK3C2G was associated with increased risk of both recurrence (HR, 2.44, 95% CI, 1.33-4.47, P=0.004) and death (HR, 2.89, 95% CI, 1.49-5.60, P=0.002). Multivariate analysis also indicated that low PIK3C2G copy number was a significant and independent predictor of OS and RFS of stage III CRC.
  
  
  CONCLUSIONS
  PIK3C2G is capable of predicting the recurrence and overall survival of stage III CRC patients receiving oxaliplatin-based therapy.
authors.affiliation: Department of General Surgery, Ruijin Hospital Affiliated Shanghai Jiaotong University School of Medicine Shanghai 200025, China.
authors.forename: Ajian
authors.initials: A
authors.lastname: Li
authors.affiliation: Department of General Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 200437, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
authors.affiliation: Department of General Surgery, Ruijin Hospital Affiliated Shanghai Jiaotong University School of Medicine Shanghai 200025, China.
authors.forename: Moubin
authors.initials: M
authors.lastname: Lin
authors.affiliation: Department of General Surgery, Ruijin Hospital Affiliated Shanghai Jiaotong University School of Medicine Shanghai 200025, China.
authors.forename: Chenbo
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Department of General Surgery, Yangpu Hospital Affiliated to Shanghai Tongji University School of Medicine Shanghai 200090, China.
authors.forename: Erjiang
authors.initials: E
authors.lastname: Tang
authors.affiliation: Center for Translational Medicine, Yangpu Hospital Affiliated to Shanghai Tongji University School of Medicine Shanghai 200090, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Peng
authors.affiliation: Department of Pathology, The Tenth People's Hospital Affiliated to Shanghai Tongji University School of Medicine Shanghai 200072, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Wei
authors.affiliation: Department of General Surgery, Yangpu Hospital Affiliated to Shanghai Tongji University School of Medicine Shanghai 200090, China.
authors.forename: Huaguang
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of General Surgery, Ruijin Hospital Affiliated Shanghai Jiaotong University School of Medicine Shanghai 200025, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Yin
keywords: PIK3C2G; colorectal cancer; overall survival; oxaliplatin; recurrence